Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
¹⁷⁷Lu-CTR-FAPI in Metastatic Solid Tumors
NCT07587996Phase 1Completed
- Sponsor
- Second Hospital of Lanzhou University
- Start
- Nov 2024
- Primary completion
- Mar 2026
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 177Lu-CTR-FAPI in metastatic solid tumors, sponsored by Second Hospital of Lanzhou University. Primary endpoints: Treatment-Emergent Adverse Events, Abnormal Vital Signs and 1 more. Started Nov 2024; status: completed.
02
Drugs
177Lu-CTR-FAPI
03
Conditions
metastatic solid tumors
Beyond the preview
Go deeper on NCT07587996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07587996.